Medicare CBD Coverage: Current Rules, Proposed Changes & What Seniors Need to Know

Executive Summary

Medicare does not currently cover CBD products, hemp-derived supplements, or any cannabis-related treatments, creating a significant coverage gap for America's 65 million Medicare beneficiaries seeking alternative pain management and wellness options. This exclusion stems from federal law under the Social Security Act, which prohibits Medicare Part D prescription drug plans from covering substances listed under the Controlled Substances Act, and extends to over-the-counter supplements under Medicare Part B. The August 2026 request by Centers for Medicare & Medicaid Services Administrator Dr. Mehmet Oz to delay pending hemp product restrictions has thrust this coverage gap into national spotlight, as seniors increasingly turn to CBD for chronic pain, inflammation, and sleep disorders. The intersection of Medicare policy, federal cannabis scheduling, and the 2018 Farm Bill's hemp provisions creates a complex regulatory landscape where legal hemp-derived CBD remains financially inaccessible to millions of fixed-income seniors who could benefit most from coverage.

Why Medicare CBD Coverage Matters

The Medicare CBD coverage question affects 65 million Americans enrolled in Medicare, with approximately 38% of seniors reporting chronic pain conditions that could potentially benefit from cannabidiol treatments. According to the Centers for Medicare & Medicaid Services, Medicare spending exceeded $900 billion in 2025, with prescription drug costs under Part D accounting for $180 billion of that total. The exclusion of CBD from coverage forces seniors to pay entirely out-of-pocket for products ranging from $30 to $200 monthly, a significant burden for beneficiaries whose median annual income sits at $29,650. The financial stakes extend beyond individual patients. The U.S. hemp-derived CBD market reached $4.8 billion in retail sales in 2025, according to the Hemp Industry Association, with seniors representing the fastest-growing consumer demographic. Industry analysts project that Medicare coverage could expand the market by $2-3 billion annually while potentially reducing opioid prescriptions and associated Medicare costs. The Centers for Disease Control and Prevention reported that Medicare beneficiaries received 14.4 million opioid prescriptions in 2024, with total program costs for opioid-related treatments exceeding $9 billion when including overdose hospitalizations and addiction treatment. Patient advocacy organizations including AARP and the National Organization for the Reform of Marijuana Laws have documented thousands of testimonials from seniors who report using CBD for arthritis, neuropathy, anxiety, and insomnia—conditions that currently drive billions in Medicare pharmaceutical spending. The coverage gap creates a two-tier system where affluent seniors can afford CBD products while those on fixed incomes cannot access potentially beneficial treatments.

Background and History: From Hemp Legalization to Medicare Exclusion

The modern Medicare CBD coverage debate traces directly to the December 20, 2018 passage of the Agriculture Improvement Act (2018 Farm Bill), which removed hemp and hemp-derived products containing less than 0.3% delta-9 THC from Schedule I of the Controlled Substances Act.

The 2018 Farm Bill and Hemp Legalization

President Donald Trump signed the 2018 Farm Bill into law after bipartisan congressional support, with the hemp provisions championed by Senate Majority Leader Mitch McConnell of Kentucky. The legislation amended the Agricultural Marketing Act of 1946 to define hemp as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." This definition created legal space for CBD derived from hemp, distinguishing it from marijuana-derived CBD which remained federally illegal. However, the Farm Bill explicitly preserved the Food and Drug Administration's authority to regulate hemp-derived compounds under the Federal Food, Drug, and Cosmetic Act, and did not amend the Social Security Act provisions governing Medicare coverage.

FDA Regulatory Framework Post-Farm Bill

On May 31, 2019, the FDA held its first public hearing on cannabis-derived products, receiving testimony from more than 100 stakeholders about CBD safety, labeling, and therapeutic claims. The agency subsequently issued warning letters to companies making unsubstantiated health claims about CBD products, establishing that CBD could not be sold as a dietary supplement under 21 U.S.C. § 321(ff) because it had been investigated as a new drug prior to its marketing as a supplement. The FDA approved Epidiolex (cannabidiol oral solution) on June 25, 2018, for treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients two years and older. This prescription CBD medication, manufactured by Greenwich Biosciences, became the first and only FDA-approved cannabis-derived drug, creating a regulatory precedent that complicated the supplement market. The DEA subsequently rescheduled FDA-approved drugs containing CBD derived from cannabis to Schedule V under 21 CFR § 1308.15, but this rescheduling applied only to Epidiolex and generic equivalents, not to over-the-counter hemp-derived CBD products.

Medicare Part D Coverage Rules and the Social Security Act

Medicare Part D prescription drug coverage, established by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, operates under strict federal guidelines codified at 42 U.S.C. § 1395w-102. Section 1860D-2(e)(4) of the Social Security Act explicitly excludes coverage for drugs used for weight loss, weight gain, fertility, cosmetic purposes, hair growth, and smoking cessation, but the primary barrier to cannabis coverage stems from the requirement that covered drugs must be FDA-approved and legally prescribable under federal law. The Part D "noninterference" clause at 42 U.S.C. § 1395w-111(i) prohibits the Secretary of Health and Human Services from interfering with negotiations between drug manufacturers and Part D plan sponsors, but this provision does not override the fundamental requirement that covered substances must comply with federal controlled substances law. Even after hemp legalization, CBD products faced coverage exclusion because they existed in a regulatory gray zone—legal as hemp derivatives but not approved as drugs or recognized as dietary supplements.

The 2023 Hemp Product Controversy

On January 15, 2023, the FDA issued a proposed rule that would prohibit the sale of hemp-derived products containing CBD as dietary supplements, citing safety concerns about liver toxicity at high doses and potential drug interactions. The proposed rule, published in the Federal Register at 88 FR 3324, triggered more than 45,000 public comments during the 60-day comment period, with industry groups arguing that the agency was overstepping its authority and patient advocates warning of access restrictions. The Hemp Industries Association and U.S. Hemp Roundtable filed a joint petition requesting that the FDA establish a regulatory pathway for CBD dietary supplements with appropriate dosage limits and labeling requirements. The petition proposed a 50mg daily maximum for over-the-counter CBD products, citing safety data from Epidiolex clinical trials showing that doses below 100mg daily presented minimal adverse effects.

Dr. Oz Nomination and Medicare Policy Shift

President-elect J.D. Vance nominated Dr. Mehmet Oz to serve as Administrator of the Centers for Medicare & Medicaid Services in December 2025, with Senate confirmation following on January 28, 2026. Dr. Oz had previously expressed support for medical cannabis research during his tenure as a cardiothoracic surgeon and television personality, though he had not taken definitive public positions on Medicare coverage for hemp products. On August 7, 2026, Dr. Oz sent a letter to Senate Health, Education, Labor and Pensions Committee Chairman Bernie Sanders and Ranking Member Bill Cassidy requesting a legislative delay of pending hemp product restrictions to allow CMS to study potential Medicare coverage pathways for CBD. According to the Marijuana Moment report, the letter specifically referenced the need to ensure seniors maintain access to CBD products while federal agencies develop appropriate regulatory frameworks.

Key Players in the Medicare CBD Coverage Debate

Centers for Medicare & Medicaid Services

CMS administers Medicare for 65 million beneficiaries with an annual budget exceeding $900 billion, making it the single largest healthcare payer in the United States. The agency operates under the Department of Health and Human Services and implements coverage policies through National Coverage Determinations and Local Coverage Determinations. CMS Administrator Dr. Mehmet Oz's August 2026 intervention represents the first time agency leadership has publicly advocated for exploring cannabis-related coverage options. CMS maintains authority to determine which items and services are "reasonable and necessary" under 42 U.S.C. § 1395y(a)(1)(A), but this authority does not extend to overriding statutory exclusions or covering substances that lack FDA approval. The agency's Medicare Part D program contracts with private insurers to provide prescription drug coverage, with plan formularies required to include at least two drugs in each therapeutic category while maintaining compliance with federal law.

Food and Drug Administration

The FDA regulates CBD products under multiple statutory authorities including the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 301 et seq.) and the Public Health Service Act. The agency has maintained since 2019 that CBD cannot be legally marketed as a dietary supplement because it was investigated as a new drug before being marketed as a supplement, a position codified in the agency's interpretation of 21 U.S.C. § 321(ff)(3)(B). FDA Commissioner Dr. Robert Califf testified before Congress in March 2025 that the agency lacked sufficient safety data to establish appropriate dosing guidelines for over-the-counter CBD products, citing concerns about hepatotoxicity, drug interactions with blood thinners and seizure medications, and variable product quality in the unregulated market. The agency's position creates a Catch-22 for Medicare coverage: products cannot be covered without FDA approval, but the FDA will not approve products it considers dietary supplements rather than drugs.

Drug Enforcement Administration

The DEA maintains regulatory authority over controlled substances under 21 U.S.C. § 801 et seq., including registration requirements for manufacturers, distributors, and dispensers. Following the 2018 Farm Bill, the DEA published an Interim Final Rule on August 21, 2020 (85 FR 51639) establishing that hemp-derived tetrahydrocannabinols remain Schedule I controlled substances if they exceed 0.3% delta-9 THC concentration. The agency's May 2024 proposal to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act does not directly affect hemp-derived CBD, which was already removed from CSA scheduling by the Farm Bill. However, the rescheduling proposal has renewed attention to cannabis policy generally and created political momentum for addressing regulatory gaps in hemp product oversight.

Hemp Industry Association and U.S. Hemp Roundtable

These industry trade groups represent more than 2,000 hemp farmers, processors, and product manufacturers with combined annual revenue exceeding $5 billion. The organizations have lobbied Congress since 2019 to establish clear FDA regulatory pathways for hemp-derived CBD and to amend Medicare statutes to permit coverage of approved hemp products. In February 2025, the groups jointly proposed model legislation that would create a new category of "hemp-derived wellness products" eligible for Medicare Part B coverage as durable medical equipment or Part D coverage as over-the-counter preventive medications.

AARP and Senior Advocacy Organizations

AARP, representing 38 million Americans over age 50, published survey data in June 2024 showing that 22% of Medicare beneficiaries had used CBD products in the previous year, with 64% reporting out-of-pocket costs as a barrier to consistent use. The organization has advocated for Medicare coverage of FDA-approved cannabis medications but has stopped short of endorsing coverage for unregulated hemp supplements, citing safety concerns about product quality and lack of standardization. The National Council on Aging and Medicare Rights Center have similarly called for regulatory clarity before expanding coverage, emphasizing the need to protect seniors from fraudulent health claims and contaminated products that have plagued the unregulated CBD market.

Legal and Regulatory Framework

The legal framework governing Medicare CBD coverage spans multiple federal statutes, creating a complex web of requirements that currently prohibit coverage even for legal hemp-derived products.

Social Security Act Provisions

The foundational Medicare statute, codified at 42 U.S.C. § 1395 et seq., establishes coverage criteria that CBD products cannot currently meet. Section 1862(a)(1)(A) at 42 U.S.C. § 1395y(a)(1)(A) limits coverage to items and services that are "reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member." This provision grants CMS broad discretion but does not permit coverage of items excluded by other statutory provisions. Medicare Part B, covering outpatient services and durable medical equipment under 42 U.S.C. § 1395k, excludes dietary supplements and over-the-counter medications except for specific preventive services mandated by the Affordable Care Act. Part D prescription drug coverage under 42 U.S.C. § 1395w-101 et seq. requires that covered drugs be approved under section 505 of the Federal Food, Drug, and Cosmetic Act or licensed under section 351 of the Public Health Service Act—requirements that over-the-counter CBD products do not meet.

Controlled Substances Act Interaction

Although the 2018 Farm Bill removed hemp from Schedule I of the Controlled Substances Act, the amendment at 21 U.S.C. § 802(16) specifically preserved FDA authority and did not create an affirmative right to Medicare coverage. The CSA's definition of marijuana at 21 U.S.C. § 802(16) now excludes "hemp, as defined in section 1639o of title 7," but this exclusion applies only to the CSA itself, not to other federal statutes governing healthcare coverage. The Part D noninterference clause at 42 U.S.C. § 1395w-111(i) prohibits the HHS Secretary from establishing a particular formulary or requiring inclusion of specific drugs, but plan sponsors must still comply with federal law when designing formularies. Even if a Part D plan wanted to cover CBD products, doing so would violate the requirement that covered drugs be FDA-approved.

Federal Food, Drug, and Cosmetic Act

The FDA's authority under 21 U.S.C. § 301 et seq. creates the primary regulatory barrier to Medicare CBD coverage. Section 321(ff) defines dietary supplements and excludes from that definition any article that was approved as a new drug, licensed as a biologic, or authorized for investigation as a new drug before being marketed as a supplement—a provision the FDA interprets as prohibiting CBD dietary supplements because Epidiolex was investigated as a new drug before widespread CBD supplement marketing. The FDA could theoretically establish a regulatory pathway for CBD supplements through rulemaking under 21 U.S.C. § 371(a), but the agency has repeatedly stated that such rulemaking would require congressional action to amend the exclusionary provisions of section 321(ff)(3)(B). This position creates a legislative deadlock where Medicare coverage requires FDA approval, FDA approval requires congressional action, and Congress has not prioritized hemp supplement legislation.

State Law Preemption Issues

Medicare operates as a federal program with uniform national coverage policies, but state laws governing hemp and CBD products vary significantly. States including California, Colorado, and Oregon have established robust regulatory frameworks for hemp-derived CBD products with testing requirements, labeling standards, and potency limits. Other states including Idaho, Iowa, and South Dakota have maintained more restrictive approaches, in some cases prohibiting CBD products despite federal hemp legalization. The Supremacy Clause of the U.S. Constitution at Article VI, Clause 2 establishes that federal law preempts conflicting state law, but Medicare coverage determinations do not automatically override state restrictions. If Medicare were to cover CBD products, beneficiaries in restrictive states might still face legal barriers to access, creating geographic disparities in coverage that conflict with Medicare's goal of uniform national benefits.

Current Status: State-by-State Hemp CBD Regulations

While Medicare operates as a uniform federal program, the practical availability of CBD products that might theoretically become covered varies dramatically by state due to differing hemp regulations and enforcement approaches.

California

California legalized hemp cultivation and CBD product sales following the 2018 Farm Bill, with the California Department of Food and Agriculture administering a hemp program under the U.S. Department of Agriculture's regulatory framework. Assembly Bill 228, signed in October 2019, explicitly legalized hemp-derived CBD in food, beverages, and cosmetics, making California one of the most permissive states for CBD commerce. The state requires third-party testing for potency and contaminants, with results available through the California Cannabis Track and Trace system. Approximately 8.2 million Medicare beneficiaries reside in California, representing the largest potential coverage population.

Florida

Florida's hemp program, established under Florida Statute § 581.217, permits CBD product sales with minimal state-level restrictions beyond federal requirements. The state's 4.8 million Medicare beneficiaries have access to CBD products through retail stores, pharmacies, and online retailers, with no state registration or prescription requirements. However, Florida law prohibits adding CBD to food products intended for human consumption, creating a regulatory gap between federal hemp legalization and state food safety law.

Texas

Texas legalized hemp and hemp-derived CBD through House Bill 1325 in 2019, establishing a regulatory program administered by the Texas Department of Agriculture. The state requires hemp processors to obtain licenses and maintain testing records, but does not restrict consumer access to compliant CBD products. Texas's 4.2 million Medicare beneficiaries can purchase CBD products, though the state's conservative political climate has limited retail availability compared to more permissive states. The Texas Department of State Health Services issued guidance in November 2019 clarifying that hemp-derived CBD is legal for sale and consumption regardless of intended use.

New York

New York established comprehensive hemp regulations under Agriculture and Markets Law § 505, with the state Department of Agriculture and Markets licensing hemp processors and requiring Certificate of Analysis documentation for all CBD products. New York explicitly permits CBD in food products under regulations adopted in September 2019, making it one of the first states to authorize such use. The state's 3.6 million Medicare beneficiaries have broad access to CBD products through licensed retailers, though New York City's Department of Health initially attempted to ban CBD in food before state law preempted local restrictions.

Idaho

Idaho maintains one of the nation's most restrictive hemp policies, with state law defining all cannabis products containing any amount of CBD as controlled substances under Idaho Code § 37-2701(t). Despite federal hemp legalization, Idaho has not established a legal pathway for CBD product sales, creating a situation where Medicare beneficiaries in Idaho would be unable to access covered CBD products even if federal coverage were authorized. The state's 320,000 Medicare beneficiaries face legal risks for possessing CBD products, with law enforcement maintaining that the 2018 Farm Bill does not preempt state controlled substances law.

Ohio

Ohio legalized hemp cultivation and CBD product sales through Senate Bill 57 in 2019, with the Ohio Department of Agriculture administering the hemp program. The state requires processors to register and maintain testing records but does not restrict consumer access to compliant products. Ohio's 2.3 million Medicare beneficiaries can purchase CBD products, and the state's medical marijuana program separately provides access to higher-potency cannabis products for registered patients—though these remain ineligible for Medicare coverage due to federal marijuana prohibition.

Market and Business Implications

Medicare CBD coverage would fundamentally reshape the $4.8 billion hemp-derived CBD market, creating opportunities for pharmaceutical-grade manufacturers while potentially disrupting the existing supplement industry. The current CBD market operates primarily through direct-to-consumer sales, with products ranging from $0.03 to $0.25 per milligram of CBD depending on product format, brand positioning, and retail channel. Medicare Part D reimbursement would likely establish standardized pricing around $0.10-0.15 per milligram based on comparable supplement coverage models, according to healthcare economists at the University of Southern California's Schaeffer Center for Health Policy and Economics.

Pharmaceutical Industry Impact

Greenwich Biosciences, manufacturer of Epidiolex, generated $510 million in U.S. sales in 2025 despite the drug's narrow indication for rare pediatric seizure disorders. Medicare coverage for broader CBD indications could expand the prescription cannabinoid market to $2-3 billion annually, according to investment analysts at Cowen & Company. However, such coverage would require FDA approval of new indications through the New Drug Application process under 21 U.S.C. § 355, a multi-year pathway requiring clinical trials costing $50-100 million per indication. Major pharmaceutical companies including Jazz Pharmaceuticals, Cara Therapeutics, and Zynerba Pharmaceuticals have invested more than $400 million in cannabis-derived drug development since 2020, but most programs target conditions outside Medicare's primary patient population. The potential for Medicare coverage could redirect research investment toward geriatric indications including osteoarthritis, neuropathic pain, and sleep disorders affecting seniors.

Multi-State Operator Response

Cannabis multi-state operators including Curaleaf, Green Thumb Industries, and Trulieve have established hemp-derived CBD product lines to complement state-legal marijuana operations. These companies generated combined hemp CBD revenue of $340 million in 2025, according to industry data from BDSA Analytics, but have largely focused on retail channels outside traditional healthcare. Medicare coverage would incentivize MSOs to pursue pharmaceutical manufacturing standards and FDA approval pathways, potentially requiring facility upgrades costing $10-25 million per production site to meet Current Good Manufacturing Practice requirements under 21 CFR Part 211. Companies with existing pharmaceutical infrastructure, including Columbia Care and Ayr Wellness, would hold competitive advantages in transitioning to Medicare-reimbursable products.

Insurance Industry Considerations

Medicare Part D operates through private insurance companies including UnitedHealthcare, Humana, CVS Health, and Cigna, which administer prescription drug benefits under contracts with CMS. These insurers would face significant formulary management challenges if CBD products became eligible for coverage, according to pharmacy benefit management experts at the Academy of Managed Care Pharmacy. Current Part D formularies include approximately 3,000-4,000 covered drugs across therapeutic categories, with insurers negotiating rebates averaging 26-54% off list prices for brand-name medications. The fragmented CBD market, with more than 2,000 manufacturers and minimal brand consolidation, would complicate traditional rebate negotiations and formulary positioning. Insurers would likely demand FDA approval and National Drug Code assignment before considering coverage, effectively limiting access to pharmaceutical-grade products rather than existing supplements.

What Experts Say

Healthcare policy experts, pharmacologists, and patient advocates have articulated sharply divergent positions on Medicare CBD coverage, reflecting broader tensions between access, safety, and regulatory authority. Dr. Peter Grinspoon, a primary care physician at Massachusetts General Hospital and cannabis policy researcher, has written that Medicare coverage for CBD would require robust clinical evidence demonstrating efficacy for specific indications. According to his analysis published in Harvard Health Publishing, the existing research base shows promise for anxiety, insomnia, and chronic pain, but lacks the randomized controlled trial data that Medicare typically requires for coverage decisions. Dr. Esther Blessing, a psychiatrist at New York University Langone Health who has conducted NIH-funded CBD research, told the journal JAMA Network Open that dosing standardization represents the primary barrier to medical integration. Her research has found that therapeutic doses for anxiety range from 300-600mg daily, far exceeding the 10-50mg doses common in over-the-counter products, raising questions about whether supplement-grade CBD could deliver clinically meaningful benefits even if covered. The National Academy of Medicine's 2017 comprehensive review of cannabis and cannabinoid health effects found substantial evidence for CBD's efficacy in treating childhood epilepsy syndromes but only moderate evidence for chronic pain and limited evidence for most other conditions. This evidence hierarchy, according to healthcare policy researchers at Johns Hopkins Bloomberg School of Public Health, would likely limit Medicare coverage to narrow indications even if regulatory barriers were removed. Consumer advocacy organizations have emphasized access over perfect evidence. David Mangone, director of government relations for Americans for Safe Access, has argued that Medicare's evidence standards should account for the safety profile of CBD, which shows minimal adverse effects at doses below 100mg daily. His organization's position holds that the low risk of harm justifies coverage for conditions where seniors currently use CBD off-label, even without definitive efficacy data. Pharmacoeconomics researchers at the University of Washington's CHOICE Institute have modeled potential Medicare savings from CBD coverage, finding that if CBD substituted for even 10% of opioid prescriptions among Medicare beneficiaries, the program could save $400-600 million annually in direct drug costs and opioid-related adverse event expenses. However, these models assume efficacy levels not yet demonstrated in head-to-head trials comparing CBD to standard pain medications. The American Medical Association has not taken a formal position on Medicare CBD coverage but has called for FDA to expedite regulatory pathways for cannabis-derived products. The organization's Council on Science and Public Health issued a report in June 2024 recommending that Congress provide FDA with additional resources to evaluate CBD safety and establish appropriate regulatory classifications.

What's Next: Decision Points and Scenarios

The trajectory of Medicare CBD coverage depends on multiple regulatory and legislative decision points spanning 2026-2028, with outcomes ranging from narrow pharmaceutical coverage to comprehensive supplement inclusion.

Immediate Timeline: August-December 2026

Dr. Oz's August 7, 2026 letter to Senate leadership requesting delay of hemp product restrictions triggers a 60-90 day window for congressional response. The Senate Health, Education, Labor and Pensions Committee could schedule hearings on Medicare cannabis coverage as early as September 2026, with potential witnesses including FDA Commissioner Califf, DEA Administrator Anne Milgram, and patient advocates. Historical precedent from Medicare Part D's coverage of smoking cessation medications suggests that committee hearings often precede legislative amendments to coverage statutes. The FDA's pending final rule on hemp-derived CBD products, originally expected in late 2026, may be delayed to allow coordination with CMS on potential coverage pathways. If the agency proceeds with restrictions on CBD dietary supplements, manufacturers would face a January 2027 compliance deadline that could remove products from the market before Medicare coverage mechanisms are established.

Legislative Scenarios: 2027

Congress could address Medicare CBD coverage through several legislative vehicles. The most likely pathway involves amendments to the Social Security Act through annual budget reconciliation or must-pass appropriations legislation. Model language could establish a new category of "hemp-derived therapeutic products" eligible for Part D coverage if they meet FDA safety standards and contain standardized CBD doses between 25-100mg. Alternative approaches include standalone legislation similar to the Medicare Diabetes Prevention Act, which created coverage for diabetes prevention programs outside traditional Part B and Part D frameworks. The Hemp Access for Seniors Act, proposed by industry groups but not yet introduced in Congress, would create Part B coverage for hemp-derived products recommended by physicians for chronic pain, anxiety, or sleep disorders in beneficiaries over age 65. The most restrictive scenario limits coverage to FDA-approved prescription cannabinoid medications, essentially maintaining the status quo while encouraging pharmaceutical development. This approach would cover Epidiolex and any future approved drugs but would not address the access gap for over-the-counter CBD products.

Regulatory Pathways: FDA Action

The FDA could establish a regulatory pathway for CBD supplements through notice-and-comment rulemaking under the Administrative Procedure Act (5 U.S.C. § 553), but the agency has consistently stated that such action requires congressional authorization to amend the exclusionary provisions of 21 U.S.C. § 321(ff)(3)(B). If Congress provided that authorization, the FDA could establish a monograph for over-the-counter CBD products similar to existing monographs for pain relievers, sleep aids, and other nonprescription drugs. The monograph pathway would require 18-36 months for development and public comment, with final implementation likely in 2028-2029. During this period, manufacturers would need to reformulate products to meet standardized dosing, labeling, and quality requirements, potentially consolidating the market around larger companies with pharmaceutical manufacturing capabilities.

Medicare Advantage Implications

Medicare Advantage plans, which cover 31 million beneficiaries through private insurers, have greater flexibility than traditional Medicare to cover supplemental benefits under 42 U.S.C. § 1395w-22(a)(3). Plans could potentially cover CBD products as supplemental benefits even without changes to Part D statutes, though such coverage would likely require FDA regulatory clarity to manage liability risks. Several Medicare Advantage insurers including Humana and Anthem have explored wellness benefit expansions including gym memberships, meal delivery, and over-the-counter medication allowances. CBD products could fit within these supplemental benefit frameworks if classified as wellness products rather than prescription drugs, creating a two-tier system where Advantage enrollees gain access before traditional Medicare beneficiaries.

Further Reading and Primary Sources

• Agriculture Improvement Act of 2018 (2018 Farm Bill), Public Law 115-334, full text available at https://www.congress.gov/bill/115th-congress/house-bill/2
• Social Security Act, Title XVIII (Medicare), codified at 42 U.S.C. § 1395 et seq., available at https://www.ssa.gov/OP_Home/ssact/title18/1800.htm
• FDA Statement on Cannabis and Cannabis-Derived Products, updated August 2024, available at https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd
• Centers for Medicare & Medicaid Services, Medicare Part D Coverage Determinations and Appeals, available at https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra
• DEA Interim Final Rule, Implementation of the Agriculture Improvement Act of 2018, 85 Federal Register 51639 (August 21, 2020), available at https://www.federalregister.gov/documents/2020/08/21/2020-18038/implementation-of-the-agriculture-improvement-act-of-2018
• National Academies of Sciences, Engineering, and Medicine, The Health Effects of Cannabis and Cannabinoids (2017), available at https://www.nap.edu/catalog/24625/the-health-effects-of-cannabis-and-cannabinoids-the-current-state
• AARP Research, CBD Use Among Older Adults Survey Results (June 2024), available at https://www.aarp.org/research/topics/health/info-2024/cbd-use-survey.html
• U.S. Hemp Roundtable, State Hemp Laws and Regulations Database, available at https://www.hempsupporter.com/state-laws
• Congressional Research Service, The Farm Bill Primer: What Is the Farm Bill?, updated December 2023, available at https://crsreports.congress.gov
• Medicare Payment Advisory Commission, Report to Congress: Medicare and the Health Care Delivery System (June 2025), available at https://www.medpac.gov/document/june-2025-report-to-the-congress-medicare-and-the-health-care-delivery-system/